Literature DB >> 17320337

The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.

Anja Mehnert1, Angela Scherwath, Lena Schirmer, Barbara Schleimer, Corinna Petersen, Frank Schulz-Kindermann, Axel R Zander, Uwe Koch.   

Abstract

OBJECTIVE: The possible association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life has been studied in high-risk breast cancer survivors 5 years following standard adjuvant (n=23) versus high-dose chemotherapy (n=24) and in early-stage breast cancer patients (n=29) (comparison group) following radiation therapy.
METHODS: A neuropsychological assessment covering attention, memory and executive functions was used together with the questionnaire for self-perceived deficits in attention (FEDA), the multidimensional fatigue inventory (MFI-20) and the EORTC-QLQ-C30.
RESULTS: Findings have shown that neuropsychological impairment is not directly associated with self-perceived cognitive deficits, fatigue and HRQOL. However, 46% of patients reported self-perceived cognitive deficits and 82% of the patients complained about cancer related fatigue. Except for reduced activity we did not find significant group differences, even though patients who received standard-dose chemotherapy had consistently higher levels of self-perceived cognitive deficits and fatigue, and the lowest HRQOL.
CONCLUSION: Results emphasize the need for psychosocial counseling and support during treatment phase and follow up care as well. Sensitive cancer-specific measures for the assessment of self-perceived cognitive deficits in different cognitive domains according to neuropsychological measurements are required. PRACTICE IMPLICATIONS: The role of self-perceived cognitive deficits and fatigue should be considered in educational interventions and counseling. Specific rehabilitation measures should be developed, implemented and evaluated in order to meet the needs of these patients and to decrease the frequency of cognitive deficits following cancer treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17320337     DOI: 10.1016/j.pec.2006.11.005

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  42 in total

Review 1.  An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors.

Authors:  Yin Ting Cheung; Earl Hsien-Jie Tan; Alexandre Chan
Journal:  Support Care Cancer       Date:  2012-04-05       Impact factor: 3.603

2.  The psychometric properties of the Korean version of the functional assessment of cancer therapy-cognitive (FACT-Cog) in Korean patients with breast cancer.

Authors:  Jin-Hee Park; Sun Hyoung Bae; Yong Sik Jung; Young-Mi Jung
Journal:  Support Care Cancer       Date:  2015-02-11       Impact factor: 3.603

Review 3.  Chemobrain: a critical review and causal hypothesis of link between cytokines and epigenetic reprogramming associated with chemotherapy.

Authors:  Xiao-Min Wang; Brian Walitt; Leorey Saligan; Agnes F Y Tiwari; Chi Wai Cheung; Zhang-Jin Zhang
Journal:  Cytokine       Date:  2015-01-05       Impact factor: 3.861

4.  Predictors of the trajectories of self-reported attentional fatigue in women with breast cancer undergoing radiation therapy.

Authors:  John D Merriman; Catherine Jansen; Theresa Koetters; Claudia West; Marylin Dodd; Kathryn Lee; Steven M Paul; Bradley E Aouizerat; Bruce A Cooper; Patrick S Swift; William Wara; Christine Miaskowski
Journal:  Oncol Nurs Forum       Date:  2010-07       Impact factor: 2.172

5.  The perceptions of Australian oncologists about cognitive changes in cancer survivors.

Authors:  Kate Smidt; Lynette Mackenzie; Haryana Dhillon; Janette Vardy; Joanne Lewis; Siew Yim Loh
Journal:  Support Care Cancer       Date:  2016-06-20       Impact factor: 3.603

6.  Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx.

Authors:  Lynne I Wagner; Robert J Gray; Joseph A Sparano; Timothy J Whelan; Sofia F Garcia; Betina Yanez; Amye J Tevaarwerk; Ruth C Carlos; Kathy S Albain; John A Olson; Matthew P Goetz; Kathleen I Pritchard; Daniel F Hayes; Charles E Geyer; E Claire Dees; Worta J McCaskill-Stevens; Lori M Minasian; George W Sledge; David Cella
Journal:  J Clin Oncol       Date:  2020-04-09       Impact factor: 44.544

7.  Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment.

Authors:  Victoria J Bray; Haryana M Dhillon; Janette L Vardy
Journal:  J Cancer Surviv       Date:  2018-05-04       Impact factor: 4.442

8.  Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy.

Authors:  Mohd Ashif Khan; Kamlesh Garg; Dinesh Bhurani; Nidhi Bharal Agarwal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-27       Impact factor: 3.000

Review 9.  Chemotherapy-related cognitive impairment in older patients with cancer.

Authors:  Kah Poh Loh; Michelle C Janelsins; Supriya G Mohile; Holly M Holmes; Tina Hsu; Sharon K Inouye; Meghan S Karuturi; Gretchen G Kimmick; Stuart M Lichtman; Allison Magnuson; Mary I Whitehead; Melisa L Wong; Tim A Ahles
Journal:  J Geriatr Oncol       Date:  2016-07-05       Impact factor: 3.599

10.  The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9.

Authors:  Debra L Barton; Kelli Burger; Paul J Novotny; Tom R Fitch; Sadhna Kohli; Gamini Soori; Mary Beth Wilwerding; Jeff A Sloan; Lisa A Kottschade; Kendrith M Rowland; Shaker R Dakhil; Daniel A Nikcevich; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2012-11-13       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.